{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:16:41Z","timestamp":1778771801609,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T00:00:00Z","timestamp":1492387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Comparative Oncology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Canine histiocytic sarcoma (<jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>) is an aggressive neoplasm that is generally associated with a poor prognosis. <jats:styled-content style=\"fixed-case\">CCNU<\/jats:styled-content> is considered first\u2010line medical therapy, although the majority of dogs ultimately develop progressive disease. The objective of this study was to evaluate the efficacy of dacarbazine as a rescue agent for <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Medical records of dogs diagnosed with HS that received at least one dose of dacarbazine were reviewed.  Information collected and analyzed included signalment, disease distribution, treatment history, dacarbazine treatments (including dose, interval and total number of cycles), adverse events, and response to treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen dogs were included, all of which had disseminated or metastatic disease and had received prior treatment with <jats:styled-content style=\"fixed-case\">CCNU<\/jats:styled-content>. Three dogs achieved partial remission for an overall response rate of 17.6%. The overall median event\u2010free survival (<jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content>) was 21\u2009days. For dogs that experienced an objective response, the <jats:styled-content style=\"fixed-case\">EFS<\/jats:styled-content> was 70\u2009days. Toxicity secondary to dacarbazine was generally mild and self\u2010limiting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the setting of advanced disease, dacarbazine appears to have modest activity against <jats:styled-content style=\"fixed-case\">HS<\/jats:styled-content> and warrants further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vco.12314","type":"journal-article","created":{"date-parts":[[2017,4,17]],"date-time":"2017-04-17T09:52:38Z","timestamp":1492422758000},"page":"77-80","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8875-4349","authenticated-orcid":false,"given":"K. A.","family":"Kezer","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Cummings School of Veterinary Medicine at Tufts University  North Grafton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. G.","family":"Barber","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Cummings School of Veterinary Medicine at Tufts University  North Grafton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Jennings","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Cummings School of Veterinary Medicine at Tufts University  North Grafton Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,17]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.39-1-74"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.43-5-632"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpa.2014.07.003"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.39-1-66"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5810.2006.00090.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb02937.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2010.0588.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5829.2009.00186.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.239.1.90"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.1990.tb00896.x"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.231.4.563"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2009.0376.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.0005.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.5326\/JAAHA-MS-5525"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.1239"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vco.12032"},{"key":"e_1_2_5_18_1","unstructured":"Vet Comp Oncol 2016 Veterinary Cooperative Oncology Group \u2013 Common terminology criteria for adverse events (VCOG\u2010CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.5326\/15473317-36-5-422"}],"container-title":["Veterinary and Comparative Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvco.12314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vco.12314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T19:49:14Z","timestamp":1694980154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vco.12314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,17]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/vco.12314"],"URL":"https:\/\/doi.org\/10.1111\/vco.12314","archive":["Portico"],"relation":{},"ISSN":["1476-5810","1476-5829"],"issn-type":[{"value":"1476-5810","type":"print"},{"value":"1476-5829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,17]]}}}